Literature DB >> 20035926

HIV protease inhibitors block oral epithelial cell DNA synthesis.

Robert J Danaher1, Chunmei Wang, Andrew T Roland, Charlotte S Kaetzel, Richard N Greenberg, Craig S Miller.   

Abstract

OBJECTIVES: Anti-retroviral therapy regimens that include HIV protease inhibitors (PIs) are associated with diverse adverse effects including increased prevalence of oral warts, oral sensorial deficits and gastrointestinal toxicities suggesting that PIs may perturb epithelial cell biology. To test the hypothesis that PIs could affect specific biological processes of oral epithelium, the effects of these agents were evaluated in several oral epithelial cell-lines.
DESIGN: Primary and immortalized oral keratinocytes and squamous carcinoma cells of oropharyngeal origin were cultured in the presence of pharmacologically relevant concentrations of PIs. Their affects on cell viability, cytotoxicity and DNA synthesis were assessed by enzymatic assays and incorporation of 5-bromo-2'-deoxyuridine (BrdU) into DNA.
RESULTS: Viability of primary and immortalized oral keratinocytes as well as squamous carcinoma cells of oropharyngeal origin was significantly reduced by select PIs at concentrations found in plasma. Of the seven PIs evaluated, nelfinavir was the most potent with a mean 50% inhibitory concentration [IC(50)] of 4.1 microM. Lopinavir and saquinavir also reduced epithelial cell viability (IC(50) of 10-20 microM). Atazanavir and ritonovir caused minor reductions in viability, while amprenavir and indinavir were not significant inhibitors. The reduced cell viability, as shown by BrdU incorporation assays, was due to inhibition of DNA synthesis rather than cell death due to cytotoxicity.
CONCLUSION: Select PIs retard oral epithelial cell proliferation in a drug and dose-dependent manner by blocking DNA synthesis. This could account for some of their adverse effects on oral health. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20035926      PMCID: PMC2818864          DOI: 10.1016/j.archoralbio.2009.12.001

Source DB:  PubMed          Journal:  Arch Oral Biol        ISSN: 0003-9969            Impact factor:   2.633


  30 in total

1.  Changing prevalence of human immunodeficiency virus-associated oral lesions.

Authors:  P D Dios; A Ocampo; C Miralles; J Limeres; I Tomás
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2000-10

2.  Oral warts rise dramatically with use of new agents in HIV.

Authors:  J Leigh
Journal:  HIV Clin       Date:  2000

3.  Effect of highly active antiretroviral therapy on frequency of oral warts.

Authors:  D Greenspan; A J Canchola; L A MacPhail; B Cheikh; J S Greenspan
Journal:  Lancet       Date:  2001-05-05       Impact factor: 79.321

Review 4.  Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.

Authors:  Ulrik Stenz Justesen
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-01       Impact factor: 4.080

Review 5.  Anti-HIV drugs for cancer therapeutics: back to the future?

Authors:  Warren A Chow; Chunling Jiang; Min Guan
Journal:  Lancet Oncol       Date:  2009-01       Impact factor: 41.316

Review 6.  HIV topic update: protease inhibitor therapy and oral health care.

Authors:  S R Porter; C Scully
Journal:  Oral Dis       Date:  1998-09       Impact factor: 3.511

7.  Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells.

Authors:  F G Hamel; J Fawcett; B T Tsui; R G Bennett; W C Duckworth
Journal:  Diabetes Obes Metab       Date:  2006-11       Impact factor: 6.577

8.  Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis.

Authors:  J R Arribas; S Hernández-Albujar; J J González-García; J M Peña; A Gonzalez; T Cañedo; R Madero; J J Vazquez; W G Powderly
Journal:  AIDS       Date:  2000-05-26       Impact factor: 4.177

9.  HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress.

Authors:  Peter Pyrko; Adel Kardosh; Weijun Wang; Wenyong Xiong; Axel H Schönthal; Thomas C Chen
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

10.  Progress towards the use of HIV protease inhibitors in cancer therapy.

Authors:  Eric J Bernhard; Thomas B Brunner
Journal:  Cancer Biol Ther       Date:  2008-05-10       Impact factor: 4.742

View more
  8 in total

1.  Antibacterial effects of blackberry extract target periodontopathogens.

Authors:  O A González; C Escamilla; R J Danaher; J Dai; J L Ebersole; R J Mumper; C S Miller
Journal:  J Periodontal Res       Date:  2012-07-19       Impact factor: 4.419

Review 2.  Current trends and new developments in HIV research and periodontal diseases.

Authors:  Mark I Ryder; Caroline Shiboski; Tzy-Jyun Yao; Anna-Barbara Moscicki
Journal:  Periodontol 2000       Date:  2020-02       Impact factor: 7.589

3.  HIV protease inhibitors alter innate immune response signaling to double-stranded RNA in oral epithelial cells: implications for immune reconstitution inflammatory syndrome?

Authors:  Robert J Danaher; Charlotte S Kaetzel; Richard N Greenberg; Chunmei Wang; Maria E C Bruno; Craig S Miller
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

4.  Impacts of HIV infection and long-term use of antiretroviral therapy on the prevalence of oral human papilloma virus type 16.

Authors:  Korntip Amornthatree; Hutcha Sriplung; Winyou Mitarnun; Wipawee Nittayananta
Journal:  J Oral Pathol Med       Date:  2011-11-18       Impact factor: 4.253

5.  Protective effects of alanyl-glutamine supplementation against nelfinavir-induced epithelial impairment in IEC-6 cells and in mouse intestinal mucosa.

Authors:  Manuel B Braga-Neto; Bruna M C Oliveira; Raphael S Rodrigues; Francisco J Noronha; Renata F Leitao; Gerly A C Brito; Aldo A Lima; Richard L Guerrant; Cirle A Warren
Journal:  Cancer Biol Ther       Date:  2012-09-17       Impact factor: 4.742

Review 6.  Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity.

Authors:  Tomas Koltai
Journal:  F1000Res       Date:  2015-01-12

7.  Comparison of epigenetic profiles of human oral epithelial cells from HIV-positive (on HAART) and HIV-negative subjects.

Authors:  Santosh K Ghosh; Thomas S McCormick; Betty L Eapen; Elizabeth Yohannes; Mark R Chance; Aaron Weinberg
Journal:  Epigenetics       Date:  2013-05-17       Impact factor: 4.528

8.  Targeting HIV-1 Protease Autoprocessing for High-throughput Drug Discovery and Drug Resistance Assessment.

Authors:  Liangqun Huang; Linfeng Li; ChihFeng Tien; Daniel V LaBarbera; Chaoping Chen
Journal:  Sci Rep       Date:  2019-01-22       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.